Treatment Patterns, Adverse Events, and Direct and Indirect Economic Burden in a Privately Insured Population of Patients with HR+/HER2- Metastatic Breast Cancer in the United States

Article

Focus Areas: Health & Wellness

Background: Real-world evidence specific to HR+/HER2- metastatic breast cancer (MBC) prior to introduction of CDK4/6 inhibitors is limited. In an effort to provide context for the introduction of new treatments, we assessed treatment patterns, adverse events, productivity loss, and direct/indirect economic burden in a privately insured population of patients with HR+/HER2- MBC.

Research design and methods: Using a retrospective cohort design, patients aged 18-64 years, selected from MarketScan databases (2007-2014), were analyzed using descriptive and multivariable methods.

Results: Among 5,563 eligible patients, endocrine therapy was the most common first-line (1L) therapy; its utilization trended downward from 63% (1L) to 23% (4L), with simultaneous increase in chemotherapy use, 25% (1L) to 50% (4L). 278 unique treatment regimens were used in the 1L setting. The average per patient monthly all-cause costs were $14,424. The 12-month indirect costs for short-term disability were substantially higher in MBC patients ($10,397) than in matched noncancer patients ($394).

Conclusion: The increasing use of chemotherapy as patients progressed to second and later lines and the substantial direct/indirect economic burden underscore an unmet need. The high number of 1L regimens highlights significant heterogeneity and a lack of consensus related to the management of HR+/HER2- MBC in routine practice.

Goyal RK, Cuyun Carter G, Nagar SP, et al. Treatment Patterns, Adverse Events, and Direct and Indirect Economic Burden in a Privately Insured Population of Patients with HR+/HER2- Metastatic Breast Cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2020. doi:10.1080/14737167.2020.1804871